12:20 p.m. ET Late Tuesday, Eli Lilly CEO David Ricks took to the stage at the J.P. Morgan Healthcare Conference to explain his views of the booming GLP-1 space. Earlier in the day, Lilly warned ...

Eli Lilly forecasts $45 billion in 2024 revenue, a 32% growth but $400 million below Q3 guidance. Mounjaro and Zepbound expected to contribute $3.5 billion and $1.9 billion, respectively, to 2024 ...

Eli Lilly CEO David Ricks joins 'Squawk on the Street' to discuss the company's drug pipeline, 2025 outlook, state of the weight loss drugs market, status of the weight loss drug pill, revised ...

SAN FRANCISCO — Eli Lilly CEO Dave Ricks on Tuesday said he believed the company could find “significant common cause” with the incoming Trump administration, including on issues around ...

CEO David Ricks said last quarter’s 45% growth in Lilly’s revenue for its Mounjaro diabetes treatment, Zepbound obesity injections and other products in the incretin market wasn’t as big as ...

Eli Lilly expects its experimental weight loss pill, orforglipron, to be approved as soon as early next year, CEO David Ricks told Bloomberg. Eli Lilly and Novo Nordisk, which dominate the market ...

The one thing David Schwimmer found that was not scary about his new series “Goosebumps: The Vanishing” was having to work with a lot of special effects. He felt that way despite never having to deal ...

In an episode of "The David Rubenstein Show: Peer to Peer Conversations," CEO Dave Ricks talks about how the company will begin studies this year to see if its weight-loss medicines can also be ...

Or sign-in if you have an account. The Canadian Institute for Historical Education hosted author David Frum for a December speech in Toronto, “settlers & colonialists,” which has now been ...